Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia

Introduction. mBRAF mCRC has the aggressive phenotype. The incidence of such mutation in Europe and the USA is around 8–14%, in Asian countries – 4–8%. The purpose of this population-based study was to determine the incidence and identifying prognostic factors in pts with mBRAF mCRC in Russia. Mater...

詳細記述

保存先:
書誌詳細
主要な著者: M. Yu. Fedyanin, К M. Ehlsnukaeva, I. A. Demidova, D. L. Stroyakovskiy, Yu. A. Shelygin, А. S. Tsukanov, М. V. Panina, V. Р. Shubin, F. V. Moiseenko, E. Yu. Karpenko, L. V. Bolotina, A. V. Kudryavtseva, М. L. Filipenko, I. P. Oskorbin, L. Yu. Vladimirova, N. N. Timoshkina, О. I. Kit, А. М. Stroganova, S. L. Dranko, А. I. Senderovich, А. А. Tryakin, S. А. Tjulandin
フォーマット: Artigo
言語:Russo
出版事項: Remedium Group LLC 2021-06-01
シリーズ:Медицинский совет
主題:
colorectal cancer
mbraf
epidemiology
prognosis
free progression survival
overall survival
オンライン･アクセス:https://www.med-sovet.pro/jour/article/view/6211
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
ロード中...

類似資料